natgillin/translations-raw huggingface dataset:
If the skin comes into contact with the solution it should be washed immediately and thoroughly with soap and water. 
Ako otopina dođe u dodir s kožom, kožu treba odmah temeljito isprati vodom i sapunom.
Patients should be advised not to drive or use machines if they feel tired or dizzy. 
Bolesnicima valja savjetovati da ne voze i da ne upravljaju strojevima ako osjete umor ili omaglicu.
The development of severe peripheral neurotoxicity requires a delay or reduction of dose (see section 4.2) 
U slučaju razvoja teške periferne neurotoksičnosti potrebno je odgoditi primjenu ili smanjiti dozu (vidjeti dio 4.2).
Dose reduction during therapy 
Smanjenje doze za vrijeme liječenja
Adverse Reactions - all Grades Very Common (Frequency %) 
Nuspojave - svi stupnjevi Vrlo često (učestalost %)
What HALAVEN is and what it is used for What you need to know before you use HALAVEN How to use HALAVEN 
Što je HALAVEN i za što se koristi Što morate znati prije nego počnete primjenjivati HALAVEN
No dose adjustments are recommended for the elderly population. 
Nema preporuka za prilagodbu doze u starije populacije.
Pregnant staff should not handle HALAVEN. 
Zdravstvene djelatnice koje su trudne ne smiju rukovati lijekom HALAVEN.
These may be signs of a condition called Stevens Johnson syndrome/toxic epidermal necrolysis. 
To mogu biti znakovi stanja koje se zove Stevens-Johnsonov sindrom/toksična epidermalna nekroliza.
Patients experiencing febrile neutropenia, severe neutropenia or thrombocytopenia, should be treated according to the recommendations in section 4.2. 
Bolesnike s febrilnom neutropenijom, teškom neutropenijom ili trombocitopenijom treba liječiti u skladu s preporukama u dijelu 4.2.
Each carton contains either 1 or 6 vials. 
Jedna kutija sadrži 1 ili 6 bočica.
The safety profile of eribulin in elderly patients (≥ 65 years of age) was similar to that of patients <65 years of age except for asthenia/fatigue which showed an increasing trend with age. 
Profil sigurnosti primjene eribulina u starijih bolesnika (u dobi od ≥ 65 godina) bio je sličan onom u bolesnika u dobi od < 65 godina, osim za asteniju/umor gdje se pokazao trend porasta s dobi.
Metabolite concentrations represented <0.6% of parent compound, confirming that there are no major human metabolites of eribulin. 
Koncentracije metabolita činile su < 0,6% ishodišnog spoja, čime se potvrdilo da u ljudi ne nastaju neki važni metaboliti eribulina.
- The active substance is eribulin. 
- Djelatna tvar je eribulin.
Eisai Manufacturing Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom. 
Eisai Manufacturing Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Ujedinjeno Kraljevstvo.
Do not use HALAVEN: - if you are allergic to eribulin mesilate or any of the other ingredients of this medicine (listed in section 6). 
Nemojte primjenjivati HALAVEN - ako ste alergični na eribulinmesilat ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) - ako dojite
The transport protein involved in this process is unknown. 
Nije poznato koji prijenosni protein sudjeluje u tom procesu.
No specific dose adjustments are recommended based on the age of the patient (see section 4.8). 
Ne postoje posebne preporuke za prilagodbu doze na temelju dobi bolesnika (vidjeti dio 4.8).
There was no difference in efficacy between eribulin and dacarbazine in patients with advanced or metastatic leiomyosarcoma. 
Nije bilo razlike u djelotvornosti između eribulina i dakarbazina u bolesnika s uznapredovalim ili metastatskim leiomiosarkomom.
Hypokalaemia, hypocalcaemia or hypomagnesaemia should be corrected prior to initiating HALAVEN and these electrolytes should be monitored periodically during therapy. 
Hipokalijemiju, hipokalcijemiju ili hipomagnezijemiju treba korigirati prije početka liječenja lijekom HALAVEN i te elektrolite povremeno određivati tijekom liječenja.
- Serious skin rashes with blistering of the skin, mouth, eyes and genitals. 
- ozbiljni kožni osipi s mjehurima po koži, u ustima, na očima i spolnim organima.
HALAVEN contains ethanol (alcohol) This medicine contains small amounts of ethanol (alcohol), less than 100 mg in a vial. 
HALAVEN sadrži etanol (alkohol) Ovaj lijek sadrži male količine etanola (alkohol), manje od 100 mg u bočici.
Patients had received at least two prior chemotherapy regimens, one of which must have been an anthracycline (unless contraindicated). 
Bolesnici su prethodno primili najmanje dva kemoterapijska režima, od kojih je jedan morao sadržavati antraciklin (osim ako je bio kontraindiciran).
The dose of eribulin should not be re-escalated after it has been reduced. 
Nakon što je doza eribulina bila smanjena, ne smije se ponovno povećavati.
Patients should be closely monitored for signs of peripheral motor and sensory neuropathy. 
Bolesnike valja pomno pratiti zbog moguće pojave znakova periferne motoričke i senzoričke neuropatije.
It must not be mixed with other medicinal products and should not be diluted in glucose 5% infusion solution. 
Ne smije se miješati s drugim lijekovima i ne smije se razrjeđivati u 5%-tnoj otopini glukoze za infuziju.
Women of childbearing potential must be advised to avoid becoming pregnant whilst they or their male partner are receiving HALAVEN and have to use effective contraception during and up to 3 months after treatment. 
Ženama reproduktivne dobi mora se savjetovati da izbjegavaju trudnoću dok one ili njihovi partneri primaju HALAVEN i napomenuti da moraju koristiti učinkovitu kontracepciju tijekom liječenja i do 3 mjeseca nakon liječenja.
Testicular toxicity has been observed in rats and dogs (see section 5.3). 
U štakora i pasa primijećena je testikularna toksičnost (vidjeti dio 5.3).
If not used immediately HALAVEN as the undiluted solution in a syringe should not normally be stored longer than 4 hours at 25°C and ambient lighting, or 24 hours at 2°C - 8°C. 
Ako se ne primijeni odmah, HALAVEN u obliku nerazrijeđene otopine u štrcaljki ne smije se u normalnim okolnostima čuvati dulje od 4 sata na temperaturi od 25°C i pri sobnom osvjetljenju ili dulje od 24 sata na temperaturi od 2°C - 8°C.
The usual dose of HALAVEN is 1.23 mg/m2, but this may be adjusted by your doctor based on your blood test results or other factors. 
Uobičajena je doza lijeka HALAVEN 1,23 mg/m2, ali liječnik je može prilagoditi ovisno o Vašim krvnim nalazima ili drugim čimbenicima.
In the EU the recommended dose refers to the base of the active substance (eribulin). 
U Europskoj uniji preporučena doza odnosi se na djelatnu tvar u obliku baze (eribulin).
This medicinal product contains small amounts of ethanol (alcohol), less than 100 mg per dose. 
Ovaj lijek sadrži male količine etanola (alkohola), manje od 100 mg po dozi.
If you have any further questions about the use of this medicine, ask your doctor. 
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku.
The European Medicines Agency has waived the obligation to submit the results of studies with eribulin in all subsets of the paediatric population in the indication of breast cancer (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka HALAVEN u svim podskupinama pedijatrijske populacije za indikaciju raka dojke (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
It may also cause future permanent fertility problems in men if they take it and they should discuss this with their doctor before starting treatment. 
HALAVEN može prouzročiti i kasnije trajne probleme s plodnošću u muškaraca koji ga primaju, te bi oni morali razgovarati sa svojim liječnikom prije početka liječenja.
An embryofoetal development study in rat confirmed the developmental toxicity and teratogenic potential of eribulin. 
Ispitivanja utjecaja na embriofetalni razvoj u štakora potvrdila su razvojnu toksičnost i teratogeni potencijal eribulina.
HALAVEN contains the active substance eribulin and is an anti-cancer medicine which works by stopping the growth and spread of cancer cells. 
HALAVEN sadrži djelatnu tvar eribulin i antitumorski je lijek koji djeluje tako da zaustavlja rast i širenje stanica raka.
Some patients with moderately or severely impaired renal function (creatinine clearance <50 ml/min) may have increased eribulin exposure and may need a reduction of the dose. 
Neki bolesnici s umjereno ili teško oštećenom funkcijom bubrega (klirens kreatinina < 50 ml/min) mogu imati povećanu izloženost eribulinu te im može biti potrebno smanjiti dozu.
In addition there were 3 fatal events of sepsis (0.2%) and one of septic shock (0.1%). 
Osim toga, smrtni ishod imala su 3 slučaja sepse (0,2%) i jedan septičnog šoka (0,1%).
The median time to Grade 2 peripheral neuropathy was 18.4 weeks. 
Medijan vremena do periferne neuropatije 2. stupnja iznosio je 18,4 tjedana.
aCox proportional hazard bStratified by geographic region, HER2/neu status 
aCoxov model proporcionalnog hazarda bStratificirano prema geografskim regijama, statusu HER2/neu
This patient group has not been studied. 
Primjena nije ispitivana u ovoj skupini bolesnika.
Cases of disseminated intravascular coagulation have been reported, typically in association with neutropenia and/or sepsis. 
Zabilježeni su slučajevi diseminirane intravaskularne koagulacije, obično povezani s neutropenijom i/ili sepsom.
HALAVEN was not studied in patients with severe hepatic impairment (Child-Pugh C). 
HALAVEN nije ispitivan u bolesnika s teškim oštećenjem jetre (Child-Pugh C).
Myelosuppression is dose dependent and primarily manifested as neutropenia (section 4.8). 
Mijelosupresija ovisi o dozi i primarno se očituje kao neutropenija (vidjeti dio 4.8).
This translated into a 2 month improvement in median OS (13.5 months for eribulin treated patients vs. 11.5 months for dacarbazine treated patients). 
To se očitovalo u poboljšanju medijana ukupnog preživljenja za 2 mjeseca (13,5 mjeseci za bolesnike liječene eribulinom naspram 11,5 mjeseci za bolesnike liječene dakarbazinom).
HALAVEN is a cytotoxic anticancer medicinal product and, as with other toxic compounds, caution should be exercised in its handling. 
HALAVEN je citotoksični antitumorski lijek i njime se, kao i s drugim toksičnim spojevima, mora rukovati s oprezom.
Additionally, in vivo, concomitant administration of ketoconazole, a Pgp inhibitor, has no effect on eribulin exposure (AUC and Cmax). 
Osim toga, in vivo, istodobna primjena ketokonazola, inhibitora Pgp-a, nema utjecaja na izloženost eribulinu (AUC i Cmax).
Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. 
Prethodna terapija morala je uključivati antraciklin i taksan kao adjuvantnu ili metastatsku terapiju, osim ako ti bolesnici nisu bili pogodni za ta liječenja.
Such elevations appeared to have occurred early with eribulin treatment in cycle 1 - 2 for the majority of these patients and whilst thought likely to be a phenomenon of adaptation to eribulin treatment by the liver and not a sign of significant liver toxicity in most patients, hepatotoxicity has also been reported. 
Čini se da su ta povišenja kod većine takvih bolesnika nastupila rano u terapiji eribulinom u 1. do 2. ciklusu, pa iako se smatralo da je to u većine bolesnika vjerojatno fenomen prilagodbe jetre na liječenje eribulinom, a ne znak značajne toksičnosti za jetru, zabilježena je i hepatotoksičnost.
The median duration of treatment was 12.0 weeks for sarcoma patients and 15.9 weeks for breast cancer patients. 
Medijan trajanja liječenja iznosio je 12,0 tjedana u bolesnika sa sarkomom, a 15,9 tjedana u bolesnika s rakom dojke.
The efficacy of HALAVEN in breast cancer is primarily supported by two randomized Phase 3 comparative studies. 
Djelotvornost lijeka HALAVEN u liječenju raka dojke prvenstveno je dokazana u dva randomizirana komparativna ispitivanja faze III.
It is unknown whether eribulin/metabolites are excreted in human or animal breast milk. 
Nije poznato izlučuju li se eribulin/metaboliti eribulina u majčino mlijeko u ljudi i mlijeko životinja.
Development of Grade 3 or 4 peripheral neuropathy occurred in 7.4% of breast cancer patients and 3.5% of sarcoma patients. 
Periferna neuropatija 3. ili 4. stupnja razvila se u 7,4% bolesnika s rakom dojke i 3,5% bolesnika sa sarkomom.
HALAVEN may cause adverse reactions such as tiredness and dizziness which may lead to minor or moderate influence on the ability to drive or use machines. 
HALAVEN može prouzročiti nuspojave kao što su umor i omaglica, zbog čega može imati mali do umjereni utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
- The other ingredients are ethanol and water for injections, with hydrochloric acid and sodium hydroxide possibly present in very small amounts. 
- Drugi sastojci su etanol i voda za injekcije, s kloridnom kiselinom i natrijevim hidroksidom koji mogu biti prisutni u vrlo malim količinama.
The pharmacokinetic properties are not dose or time dependent in the range of eribulin doses of 0.22 to 3.53 mg/m2. 
Farmakokinetička svojstva ne ovise o dozi niti o vremenu primjene u rasponu doza eribulina od 0,22 do 3,53 mg/m2.
Includes preferred terms of peripheral neuropathy, peripheral motor neuropathy, polyneuropathy, paraesthesia, peripheral sensory neuropathy, peripheral sensorimotor neuropathy and demyelinating polyneuropathy d 
Uključuje preporučene izraze za perifernu neuropatiju, perifernu motoričku neuropatiju, polineuropatiju, paresteziju, perifernu senzoričku neuropatiju, perifernu senzomotoričku neuropatiju i demijelinizirajuću polineuropatiju.
Women of childbearing age should use effective contraception during and up to 3 months after treatment with HALAVEN. 
Žene u reproduktivnoj dobi moraju koristiti učinkovitu kontracepciju za vrijeme liječenja i do 3 mjeseca nakon završetka liječenja lijekom HALAVEN.
Eribulin does not inhibit the CYP enzymes CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 2E1 at relevant clinical concentrations. 
Eribulin ne inhibira CYP enzime CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 ili 2E1 u klinički značajnim koncentracijama.
From a microbiological point of view unless the method of opening precludes the risk of microbial contamination the product should be used immediately. 
S mikrobiološkog stajališta, lijek se mora odmah primijeniti osim kad način otvaranja bočice sprječava rizik od mikrobiološke kontaminacije.
In liposarcoma the efficacy of eribulin is supported by the pivotal Phase 3 sarcoma study (Study 309). 
Djelotvornost eribulina kod liposarkoma potkrijepljena je ključnim ispitivanjem sarkoma faze III (Ispitivanje 309).
The median time to Grade 2 peripheral neuropathy was 12.6 weeks (post 4 cycles). 
Medijan vremena do nastanka periferne neuropatije 2. stupnja iznosio je 12,6 tjedana (nakon 4 ciklusa).
HALAVEN should not be used during pregnancy unless clearly necessary and after a careful consideration of the needs of the mother and the risk to the foetus. 
HALAVEN se ne smije primjenjivati tijekom trudnoće, osim ako je to neophodno i tek nakon pažljivog razmatranja potrebe liječenja majke i rizika za fetus.
Eribulin was not mutagenic in vitro in the bacterial reverse mutation assay (Ames test). 
Eribulin nije izazvao mutacije in vitro na testu povratnih mutacija u bakterija (Amesov test).
Where Grade 3 or 4 reactions occurred, the actual total frequency and the frequency of Grade 3 or 4 reactions are given. 
Ako su se pojavile nuspojave 3. ili 4. stupnja, prikazana je njihova stvarna ukupna učestalost i učestalost nuspojava 3. ili 4. stupnja.
If not used immediately, in-use storage times and conditions are the responsibility of the user. 
Ako se lijek ne primijeni odmah, trajanje i uvjeti čuvanja bočice nakon otvaranja odgovornost su korisnika.
The overall survival in patients in HER2 negative and HER2 positive patients in the eribulin and control groups in Study 305 and Study 301 is shown below: 
Ukupno preživljenje u bolesnika s HER2-negativnim i HER2-pozitivnim statusom u skupini koja je primala eribulin i kontrolnoj skupini u Ispitivanju 305 i Ispitivanju 301 prikazano je ispod:
Mouth ulceration Pancreatitis 
Ulceracije u ustima Pankreatitis
A fertility study was not conducted with eribulin, but based on non-clinical findings in repeated-dose studies where testicular toxicity was observed in both rats (hypocellularity of seminiferous epithelium with hypospermia/aspermia) and dogs, male fertility may be compromised by treatment with eribulin. 
Nisu provedena ispitivanja utjecaja eribulina na plodnost, ali na temelju nekliničkih nalaza u ispitivanjima ponovljene doze u kojima je bila primijećena testikularna toksičnost u štakora (hipocelularnost epitela sjemenih kanalića s hipospermijom/aspermijom) i pasa, liječenje eribulinom može oštetiti plodnost muškaraca.
Chest pain Influenza like illness 
Bol u prsištu Bolest nalik gripi
The neutropenia observed was reversible and not cumulative; the mean time to nadir was 13 days and the mean time to recovery from severe neutropenia (< 0.5 x 109/l) was 8 days. 
Primijećena neutropenija bila je reverzibilna i nije bila kumulativna; prosječno vrijeme smanjenja broja neutrofila na najniže vrijednosti iznosilo je 13 dana, a prosječno vrijeme do oporavka od teške neutropenije (< 0,5 x 109/l) iznosilo je 8 dana.
HALAVEN must not be used during breast-feeding because of the possibility of risk to the child. 
HALAVEN ne smijete primati za vrijeme dojenja zbog mogućeg rizika za dijete.
Both adverse reactions resolved with supportive care. 
Obje nuspojave riješene su s pomoću potpornih mjera.
Other medicines and HALAVEN Tell your doctor if you are using, have recently used or might use any other medicines. 
Obavijestite svog liječnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Caution and monitoring for adverse events is recommended with concomitant use of substances that have a narrow therapeutic window and that are eliminated mainly via CYP3A4-mediated metabolism (eg alfentanil, cyclosporine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus). 
Oprez i praćenje zbog mogućih štetnih događaja preporučuju se pri istodobnoj primjeni tvari uske terapijske širine te koje se eliminiraju uglavnom putem metabolizma posredovanog enzimom CYP3A4 (npr. alfentanil, ciklosporin, ergotamin, fentanil, pimozid, kinidin, sirolimus, takrolimus).
From spontaneous reporting c 
Iz spontanih prijava.
Of the 1559 breast cancer patients treated with the recommended dose of eribulin, 283 patients (18.2%) were ≥ 65 years of age. 
Od 1559 bolesnika s rakom dojke liječenih preporučenom dozom eribulina, 283 bolesnika (18,2%) bilo je u dobi od ≥ 65 godina.
Unless otherwise noted, the table shows the incidence rates of adverse reactions observed in breast cancer and soft tissue sarcoma patients who received the recommended dose in Phase 2 and Phase 3 studies. 
Ako nije navedeno drugačije, u sljedećoj su tablici prikazane stope incidencije nuspojava primijećenih u bolesnika s rakom dojke i sarkomom mekog tkiva koji su primili preporučenu dozu u ispitivanjima faze II i faze III.
ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias or concomittant treatment with medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. 
EKG praćenje preporučuje se ako se terapijom započinje u bolesnika s kongestivnim zatajenjem srca, bradiaritmijama ili u onih koji istodobno uzimaju lijekove za koje se zna da produljuju QT interval, uključujući antiaritmike klase Ia i III i u onih s poremećajem elektrolita.
In some patients with normal/abnormal liver enzymes prior treatment with eribulin, increased levels of liver enzymes have been reported with initiation of eribulin treatment. 
U nekih bolesnika s normalnim/poremećenim jetrenim enzimima prije liječenja eribulinom, povišene razine jetrenih enzima zabilježene su pri započinjanju liječenja eribulinom.
Out of the 404 sarcoma patients, 2 patients discontinued treatment with eribulin due to peripheral neuropathy. 
Od 404 bolesnika sa sarkomom, 2 bolesnika prekinula su liječenje eribulinom zbog periferne neuropatije.
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates. 
Eribulin inhibira mikrotubule u fazi rasta i pritom ne utječe na fazu skraćivanja te cijepa tubulin u neproduktivne agregate.
The plasma protein binding of eribulin (100-1000 ng/ml) ranged from 49% to 65% in human plasma. 
Vezanje eribulina za proteine plazme (100 - 1000 ng/ml) u ljudi kretalo se u rasponu od 49% do 65%.
Dose related increased number of resorptions and decreased foetal weight were observed at doses ≥ 0.088 mg/kg and increased incidence of malformations (absence of lower jaw, tongue, stomach and spleen) was recorded at 0.133 mg/kg. 
Povećana resorpcija fetusa i smanjena tjelesna težina fetusa ovisne o dozi primijećene su pri dozama ≥ 0,088 mg/kg, a povećana incidencija malformacija (nedostatak donje čeljusti, jezika, želuca i slezene) bila je zabilježena pri dozi od 0,133 mg/kg.
Eribulin has a low clearance (range of means 1.16 to 2.42 l/h/m2). 
Eribulin ima mali klirens (raspon prosječnih vrijednosti od 1,16 do 2,42 l/h/m2).
Febrile neutropenia occurred in < 5% of patients treated with eribulin. 
Febrilna neutropenija razvila se u < 5% bolesnika liječenih eribulinom.
HALAVEN is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1). 
HALAVEN je indiciran u liječenju odraslih bolesnika s neresektabilnim liposarkomom koji su prethodno primili terapiju koja sadrži antraciklin (osim ako nije bilo prikladno) zbog uznapredovale ili metastatske bolesti (vidjeti dio 5.1).
There are no data from the use of eribulin in pregnant women. 
Nema podataka o primjeni eribulina u trudnica.
Other undesirable effects include fatigue, alopecia, increased liver enzymes, sepsis and musculoskeletal pain syndrome. 
Ostale nuspojave uključuju umor, alopeciju, povišene jetrene enzime, sepsu i sindrom mišićno-koštanog bola.
However it has been shown that at clinically relevant concentrations eribulin is not a Pgp inhibitor in vitro. 
Međutim, pokazalo se da u klinički značajnim koncentracijama eribulin nije inhibitor Pgp-a in vitro.
Talk to your doctor or nurse before using HALAVEN: - if you have liver problems - if you have a fever or an infection - if you experience numbness, tingling, prickling sensations, sensitivity to touch or muscle weakness - if you have heart problems 
Obratite se svom liječniku ili medicinskoj sestri prije nego primijenite HALAVEN: - ako imate tegobe s jetrom - ako imate vrućicu ili infekciju - ako osjetite utrnulost, trnce, žmarce, razvijete osjetljivost na dodir ili mišićnu slabost - ako imate srčane tegobe
Severe hepatic impairment (Child-Pugh C) has not been studied but it is expected that a more marked dose reduction is needed if eribulin is used in these patients. 
Primjena u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh C) nije se ispitivala, ali smatra se da je dozu potrebno još više smanjiti ako se eribulin primjenjuje u ovih bolesnika.
See section 4.2 for treatment recommendations. 
Vidjeti dio 4.2 za preporuke za liječenje.
HALAVEN may cause serious birth defects and should not be used if you are pregnant unless it is thought clearly necessary after carefully considering all the risk to you and the baby. 
HALAVEN može prouzročiti ozbiljne urođene mane i ne smijete ga primati za vrijeme trudnoće, osim ako se nakon pažljivog razmatranja svih rizika za Vas i Vaše dijete nije jasno pokazalo da je liječenje neophodno.
It should not be diluted in glucose 5% infusion solution. 
Ne smije se razrjeđivati pomoću 5%-tne otopine glukoze za infuziju.
In the 404 sarcoma patient population, 90 patients (22.3%) treated with eribulin were ≥ 65 years of age. 
U populaciji od 404 bolesnika sa sarkomom, 90 bolesnika (22,3%) liječenih eribulinom bilo je u dobi od ≥ 65 godina.